# Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

> **NCT04577326** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 14 (actual)

## Conditions studied

- Malignant Pleural Mesothelioma (MPM)

## Interventions

- **DRUG:** cyclophosphamide
- **BIOLOGICAL:** CAR T cells

## Key facts

- **NCT ID:** NCT04577326
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-30
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04577326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04577326, "Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04577326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*